Per the WSJ: the EpiPen rival Auvi-Q from Kaleo is set to reenter the market next month after a recall last year due to manufacturing issues. The list price is way higher than the EpiPen — but the company claims it will put a program in place to make sure no one pays more than $360 out of pocket, and many won't pay anything at all.
